ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Pharmacyclics, Inc." (PCYC) Report Updated: Oct 19, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Pharmacyclics, Inc." (PCYC)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors: FOLD, MACK, CBPO, MNOV

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"Pharmacyclics, Inc."© quotemedia

Company Profile

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Its principal products in clinical development include ibrutinib (PCI-32765), which is initiating Phase III studies in hematologic malignancies; a BTK inhibitor lead optimization program targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in phase II clinical trial for the treatment of pancreatic cancer; and a HDAC inhibitor abexinostat, which is in Phase I and II clinical trials for the treatment of solid tumors and hematological malignancies. The companyĺs clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and other structurally related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; co-operative research and development agreement with National Cancer Institute to develop ibrutinib; and license agreement with the University of Texas to develop and commercialize porphyrins, expanded porphyrins, and other porphyrin-like substances. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.

Recent News: "Pharmacyclics, Inc."